Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | KMO | O15229 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29979975 | 0.87 | TP53 (0.41) | ADORA2AADORA1ADORA2BKDM1AMAOB | |
| SCHEMBL29979978 | 0.87 | TP53 (0.41) | ADORA2AADORA1ADORA2BKDM1AMAOB | |
| SCHEMBL29899268 | 0.87 | BRD4 (0.37) | — | |
| SCHEMBL27088387 | 0.87 | TP53 (0.41) | ADORA2AADORA1ADORA2BKDM1AMAOB | |
| SCHEMBL2024760 | 0.84 | — | — | |
| SCHEMBL24216045 | 0.82 | HSD17B10 (0.31) | — | |
| SCHEMBL1336095 | 0.80 | IDO1 (0.50) | TSHRALDH1A1GFERKMOSMN1; SMN2 | |
| SCHEMBL27088378 | 0.80 | CYP19A1 (0.40) | TSHRALDH1A1SMN1; SMN2IDO1POLB | |
| SCHEMBL29979970 | 0.80 | CYP19A1 (0.40) | TSHRALDH1A1SMN1; SMN2IDO1POLB | |
| SCHEMBL5612785 | 0.78 | RPA1 (0.44) | SMN1; SMN2CYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143578-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2005-06-30 | — | — | US | claimed |
| EP-1434772-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2005-05-04 | — | — | EP | claimed |
| US-20040192914-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2004-09-30 | — | — | US | claimed |
| EP-1434772-A1 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2004-07-07 | — | — | EP | claimed |
| WO-2003031434-A1 | COMPOUNDS AND METHODS | SMITH KLINE BEECHAM CORPORATION (US) | 2003-04-17 | — | — | WO | claimed |
| US-9982015-B2 | Cyclin based inhibitors of CDK2 and CDK4 | UNIVERSITY OF SOUTH CAROLINA (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170218018-A1 | CYCLIN BASED INHIBITORS OF CDK2 AND CDK4 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-08-03 | — | — | US | disclosed |
| US-9376465-B2 | Cyclin based inhibitors of CDK2 and CDK4 | UNIVERSITY OF SOUTH CAROLINA (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150011730-A1 | Cyclin Based Inhibitors of CDK2 and CDK4 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-01-08 | — | — | US | disclosed |
| US-20140296484-A1 | Cyclin Based Inhibitors of CDK2 and CDK4 | UNIVERSITY OF SOUTH CAROLINA (US) | 2014-10-02 | — | — | US | disclosed |
| US-20130289240-A1 | Cyclin Based Inhibitors of CDK2 and CDK4 | UNIVERSITY OF SOUTH CAROLINA | 2013-10-31 | — | — | US | disclosed |
| US-20050143578-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2005-06-30 | — | — | US | disclosed |
| EP-1434772-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2005-05-04 | — | — | EP | disclosed |
| US-20040192914-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2004-09-30 | — | — | US | disclosed |
| EP-1434772-A1 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2004-07-07 | — | — | EP | disclosed |
| WO-2003031434-A1 | COMPOUNDS AND METHODS | SMITH KLINE BEECHAM CORPORATION (US) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011730-A1 | Cyclin Based Inhibitors of CDK2 and CDK4 | CDK4, CDK2, CDK8 | TSHR 1652/4885ALDH1A1 4528/4885GFER 3752/4885 |
| US-20040192914-A1 | Compounds and methods | METAP2, METAP1, DNPEP | TSHR 2272/4885ALDH1A1 677/4885GFER 3537/4885 |
| US-20130289240-A1 | Cyclin Based Inhibitors of CDK2 and CDK4 | CDK4, CDK2, CDK8 | TSHR 1652/4885ALDH1A1 4528/4885GFER 3752/4885 |
| US-20170218018-A1 | CYCLIN BASED INHIBITORS OF CDK2 AND CDK4 | CDK4, CDK2, CDK8 | TSHR 1652/4885ALDH1A1 4528/4885GFER 3752/4885 |
| US-20140296484-A1 | Cyclin Based Inhibitors of CDK2 and CDK4 | CDK4, CDK2, CDK8 | TSHR 1652/4885ALDH1A1 4528/4885GFER 3752/4885 |
| US-20050143578-A1 | Compounds and methods | METAP2, METAP1, DNPEP | TSHR 2470/4885ALDH1A1 977/4885GFER 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.